Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

Neil P. Shah; John Nicoll; Bhushan Nagar; M. Gorre; Ronald Paquette; John Kuriyan; Charles L. Sawyers

doi:10.1016/s1535-6108(02)00096-x

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

著者: Neil P. Shah, John Nicoll, Bhushan Nagar, M. Gorre, Ronald Paquette, John Kuriyan, Charles L. Sawyers - Cancer Cell 2002 被引用: 1,625

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia | Litlas